A leap into the chemical space of protein-protein interaction inhibitors.

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) (2015) 0.99

Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology. Mol Inform (2014) 0.90

Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88

Structural properties of non-traditional drug targets present new challenges for virtual screening. J Chem Inf Model (2013) 0.83

Scaling the druggability landscape of human bromodomains, a new class of drug targets. J Med Chem (2012) 0.80

2P2I HUNTER: a tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine. J R Soc Interface (2013) 0.80

HADDOCK(2P2I): a biophysical model for predicting the binding affinity of protein-protein interaction inhibitors. J Chem Inf Model (2014) 0.79

Electrostatic similarities between protein and small molecule ligands facilitate the design of protein-protein interaction inhibitors. PLoS One (2013) 0.79

Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Sci Rep (2017) 0.75

Imbalance in chemical space: How to facilitate the identification of protein-protein interaction inhibitors. Sci Rep (2016) 0.75

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00

An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40

Principles of protein-protein interactions. Proc Natl Acad Sci U S A (1996) 14.51

A hot spot of binding energy in a hormone-receptor interface. Science (1995) 10.41

BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res (2006) 10.36

Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem (2002) 6.85

An empirical framework for binary interactome mapping. Nat Methods (2008) 6.59

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 6.54

The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov (2007) 6.27

Estimating the size of the human interactome. Proc Natl Acad Sci U S A (2008) 3.66

Diversity of protein-protein interactions. EMBO J (2003) 3.35

Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett (2008) 2.17

Transient protein-protein interactions: structural, functional, and network properties. Structure (2010) 2.07

Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci U S A (2011) 1.95

Protein-protein interactions as targets for small molecule drug discovery. Biopolymers (2006) 1.68

Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des (2009) 1.64

Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel (2008) 1.63

Ligand binding efficiency: trends, physical basis, and implications. J Med Chem (2008) 1.59

Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol (2011) 1.49

Assessing helical protein interfaces for inhibitor design. J Am Chem Soc (2011) 1.46

Predicting druggable binding sites at the protein-protein interface. Drug Discov Today (2008) 1.45

From fragment to clinical candidate--a historical perspective. Drug Discov Today (2009) 1.42

Inhibition of protein-protein interactions using designed molecules. Chem Soc Rev (2009) 1.40

Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. PLoS One (2010) 1.29

Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today (2009) 1.27

Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem Biol (2012) 1.27

Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol (2010) 1.24

The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17

Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Curr Top Med Chem (2007) 1.16

The overlap of small molecule and protein binding sites within families of protein structures. PLoS Comput Biol (2010) 1.12

Cheminformatics approaches to analyze diversity in compound screening libraries. Curr Opin Chem Biol (2010) 1.06

Aromatic-aromatic interactions in proteins: beyond the dimer. J Chem Inf Model (2011) 1.01

The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics (2011) 1.00

Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Protein Pept Sci (2008) 0.98

Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J Med Chem (2007) 0.92

Topography-biased compound library design: the shape of things to come? Drug Discov Today (2007) 0.81

Identification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interaction. J Biol Chem (2012) 0.76

Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut (1999) 1.55

Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene (2001) 1.26

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol (1998) 0.99

Permissiveness of human biliary epithelial cells to infection by hepatitis C virus. Hepatology (1999) 0.98

SERCA1 truncated proteins unable to pump calcium reduce the endoplasmic reticulum calcium concentration and induce apoptosis. J Cell Biol (2001) 0.83

Significance of repeatedly normal aminotransferase activities in HCV-infected patients. J Clin Gastroenterol (1999) 0.77

1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome. Curr Med Chem (2013) 0.76

AMMOS software: method and application. Methods Mol Biol (2012) 0.75